343 related articles for article (PubMed ID: 19828525)
1. Balancing innovation, access, and profits--market exclusivity for biologics.
Engelberg AB; Kesselheim AS; Avorn J
N Engl J Med; 2009 Nov; 361(20):1917-9. PubMed ID: 19828525
[No Abstract] [Full Text] [Related]
2. Market exclusivity for biologics.
Wheadon DE
N Engl J Med; 2010 Feb; 362(7):661; author reply 661-2. PubMed ID: 20164494
[No Abstract] [Full Text] [Related]
3. Intellectual property law in Israel, and US and European objections: Market exclusivity vs. data exclusivity.
Morag-Sela T; Cohn I; Kowalski TJ; Jarecki-Black J; Clyde-Watson Z
Nat Biotechnol; 2004 Dec; 22(12):1591-2. PubMed ID: 15583670
[No Abstract] [Full Text] [Related]
4. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
Dinh TQ
Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
[No Abstract] [Full Text] [Related]
5. Intellectual property. Balancing innovation and access: patent challenges tip the scales.
Higgins MJ; Graham SJ
Science; 2009 Oct; 326(5951):370-1. PubMed ID: 19833944
[No Abstract] [Full Text] [Related]
6. Patents: a threat to innovation?
Manocaran M
Science; 2010 Jan; 327(5961):31-2; author reply 32. PubMed ID: 20044557
[No Abstract] [Full Text] [Related]
7. Market watch: Sales of biologics to show robust growth through to 2013.
Goodman M
Nat Rev Drug Discov; 2009 Nov; 8(11):837. PubMed ID: 19876035
[No Abstract] [Full Text] [Related]
8. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
McCabe AR
Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
[No Abstract] [Full Text] [Related]
9. Bills target biosimilar drugs.
Wadman M
Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
[No Abstract] [Full Text] [Related]
10. Using market-exclusivity incentives to promote pharmaceutical innovation.
Kesselheim AS
N Engl J Med; 2010 Nov; 363(19):1855-62. PubMed ID: 21047231
[No Abstract] [Full Text] [Related]
11. A generic problem.
Hanauer SB
Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
[No Abstract] [Full Text] [Related]
12. Patent watch.
Harrison C
Nat Rev Drug Discov; 2008 Nov; 7(11):882-3. PubMed ID: 18974746
[No Abstract] [Full Text] [Related]
13. Policy on 180-day marketing exclusivity for drugs marketed under abbreviated new drug applications; clarification--FDA. Clarification.
Fed Regist; 1997 Nov; 62(229):63268-9. PubMed ID: 10177950
[TBL] [Abstract][Full Text] [Related]
14. 'Follow-on biologics': ensuring continued innovation in the biotechnology industry.
Manheim BS; Granahan P; Dow KJ
Health Aff (Millwood); 2006; 25(2):394-404. PubMed ID: 16610097
[TBL] [Abstract][Full Text] [Related]
15. US policy may encourage counterfeit drugs.
Bouchie A
Nat Biotechnol; 2003 Feb; 21(2):121. PubMed ID: 12560826
[No Abstract] [Full Text] [Related]
16. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
Apel BT
Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458
[TBL] [Abstract][Full Text] [Related]
17. Delaying generic competition--corporate payoffs and the future of Plavix.
Shuchman M
N Engl J Med; 2006 Sep; 355(13):1297-300. PubMed ID: 17005945
[No Abstract] [Full Text] [Related]
18. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity.
Fernandez DS; Huie JT
Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155
[No Abstract] [Full Text] [Related]
19. SuperGenerics: a better alternative for biogenerics.
Charles SA
Drug Discov Today; 2005 Apr; 10(8):533-5. PubMed ID: 15837591
[No Abstract] [Full Text] [Related]
20. The ongoing regulation of generic drugs.
Frank RG
N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
[No Abstract] [Full Text] [Related]
[Next] [New Search]